Havt et al. 10.1073/pnas.0506844102. |
Fig. 3. Real-time RT-PCR analysis of splice variant (SV)1 (lane A), SV2 (lane B), SV3 (lane C), SV4 (lane D), pituitary growth hormone-releasing hormone receptor (pGHRH-R) (lane E), growth hormone (GH)-releasing hormone (GHRH) (lane F), and b-actin (lane G) in two samples each of xenografted tumor tissues of human non-Hodgkin’s lymphomas (HT and RL), pancreatic cancer (MiaPaCa-2), glioblastoma (DBTRG-05), small-cell lung cancers (SCLCs) (H82 and H345), and in normal human samples of prostate (P), kidney (K), lung (L), liver (Li), and pituitary (Pi). The DNA molecular weight marker is shown in lane M. All PCRs yielded products of expected sizes of 523, 526, 245, 120, 145, 150, and 140 bp for SV1, SV2, SV3, SV4, pGHRH-R, GHRH, and b-actin, respectively. Negative controls with no RNA in the reverse transcriptase reaction and no cDNA in the PCR are shown in lane NC.
Table 5. Binding values for the pituitary GHRH-R-specific antisera to radiolabeled pGHRH-R-hapten
Antiserum | Batch 1 | Batch 2 | Batch 3 | Batch 4 | Batch 5 | Batch 6 | Batch 7 | Batch 8 |
JH-2319 | 32 | 32 | 19 | 24 | 33 | 31 | 20 | 22 |
JH-2320 | 57 | 54 | 47; 30; 20; 12 | 39; 24; 14; 10 | 39 | 27 | 31 | 38 |
JH-2321 | 76 | 77 | 63; 55; 42; 32 | 60; 52; 37; 27 | 77; 64; 49; 38 | 70; 56; 37; 31 | 68; 57; 40; 31; 22 | 67; 63; 47; 35; 25 |
JH-2322 | 33 | 33 | 37 | 38 | 47; 32; 23 | 42; 27; 18 | 39; 24 | 47; 29; 19 |
Binding values of the antisera at a dilution of 1:56,000 and at higher dilutions, where measured (at dilutions of 1:56,000; 1:112,000; 1:224,000; 1:336,000; 1:448,000), are shown as the percentage of bound radioactivity to total radioactivity.